L&T emerges lowest bidder for 400kV Kuwait solar project
Kuwait's Ministry of Electricity, Water, and Renewable Energy has announced that Larsen & Toubro (L&T) has emerged as the lowest bidder for its Al Shaqaya Solar Power Generation Station 400 kV Overhead Transmission Line (OHTL) project.
The leading Indian construction and engineering conglomerate had set a bid value of KD41.45 million ($135.2 million) for the project.
An innovative development, the Shagaya Renewable Energy Project, is being developed by the Kuwait Institute for Scientific Research (KISR).
It aims to link the Al Shaqaya solar power station to the main substation in Al Wafra (Z) through the installation of a 400 kV OHTL.
In the first phase, the project aims to generate approximately 3.2GW of electricity using renewable sources by 2030, it added.- TradeArabia News Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Tribune
7 hours ago
- Daily Tribune
Modi opens Kashmir rail link
Prime Minister Narendra Modi made his first visit to Kashmir yesterday since a conflict with arch-rival Pakistan, opening a strategic railway line to the region he called 'the crown jewel of India'. Modi launched a string of projects worth billions of dollars for the northern territory. Nuclear-armed India and Pakistan fought a four-day conflict last month, their worst standoff since 1999, before a ceasefire was agreed on May 10. 'Pakistan will never forget... its shameful loss,' the premier told crowds a month since India launched strikes on its neighbour after an attack on tourists in Kashmir. 'Friends, today's event is a grand festival of India's unity and firm resolve,' Modi said after striding across the soaring bridge to formally launch it for rail traffic. 'This is a symbol and celebration of rising India,' he said of the Chenab Bridge which connects two mountains. The Chenab span is the 'world's highest railway arch bridge', sitting 359 metres (1,117 feet) above a river. While several road and pipeline bridges are higher, Guinness World Records confirmed that Chenab trumps the previous highest railway bridge, the Najiehe in China. Modi called it 'an extraordinary feat of architecture' that 'will improve connectivity' by providing the first rail link from the Indian plains up to mountainous Kashmir. With 36 tunnels and 943 bridges, the new railway runs for 272 kilometres (169 miles) and connects Udhampur, Srinagar and Baramulla. It is expected to halve the travel time between the town of Katra in the Hindu-majority Jammu region and Srinagar, the main city in Kashmir, to around three hours. The new route will facilitate the movement of people and goods, as well as troops, that was previously possible only via treacherous mountain roads and by air.
Daily Tribune
7 hours ago
- Daily Tribune
India's central bank cuts rates more than expected to boost growth
India India's central bank cut interest rates more than expected yesterday, citing muted inflation and a need to kickstart economic growth as the impact of US tariffs weighed on the country's outlook. The Reserve Bank of India (RBI) lowered the benchmark repo rate, the level at which it lends to commercial banks, by 50 basis points to 5.5%. A majority of analysts had expected 25-basis-point reduction. The cut was its third in a row and comes a week after government data showed India's economy expanded at its slowest pace for four years in the fiscal year that ended in March. And while the January-March quarter showed signs of a rebound, with forecast-topping 7.4% year-on-year growth, analysts said US President Donald Trump's sweeping tariffs posed risks to the outlook. Easing price concerns have also allowed the RBI to concentrate on growth, with retail inflation dropping to a near sixyear-low of 3.16% in April. Bank governor Sanjay Malhotra said India's growth remained 'lower than our aspirations' in a 'challenging global environment' and that it was necessary to continue stimulating domestic consumption and investment. 'This changed growth inflation dynamics calls for not only continuing with the policy easing, but also frontloading the rate cuts to support growth,' Malhotra said. He added that the monetary policy committee had changed its stance from 'accommodative' to 'neutral', which implies a rate cut is not guaranteed at its next review meeting. The central bank also threw in a liquidity-boosting measure by cutting the cash reserve ratio, the proportion of deposits that banks must set aside with the RBI, by 100 basis points to 3%. The RBI cut rates for the first time in nearly five years in February and followed up with another reduction in April. The Indian government has forecast above-average monsoon rains, which observers say should help growth, as higher agricultural output will aid the rural economy and keep vegetable prices stable. But Trump's protectionist policies could add to growth pressures. While New Delhi is not a manufacturing powerhouse, experts believe that US tariffs will hurt billions of dollars of Indian exports across different sectors including gems and jewellery, electronics and seafood. India is hammering out the first tranche of a trade deal with Washington and negotiators have made several trips over the past three months. Local media reports say that while the White House is pushing for India to drop levies on a range of products, including agricultural produce and automobiles, New Delhi is seeking greater access for labour-intensive exports such as textiles and footwear.
Daily Tribune
4 days ago
- Daily Tribune
New hope for patients with less common breast cancer
A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported Monday. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new firstline therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15–20% of all breast cancer cases. HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. 'Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for,' oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This 'smart bomb' strategy allows the drug to target cancer cells directly. 'You can bind to the cancer cell and dump all that chemo right into the cancer cells,' explained Tolaney. 'Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much.' Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a 'second-line' option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 percent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44% compared to standard care. Fifteen percent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5% in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimizing how long patients remain on the treatment, particularly those showing complete remission. 'This represents a new firstline standard treatment option for HER2-positive metastatic breast cancer,' said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study.
